Can I Take Ashwagandha with Crestor (Rosuvastatin)?

How Rosuvastatin Is Metabolized (And Why It Matters for Supplements)

Rosuvastatin has an unusually clean metabolic profile compared with other statins. The drug is absorbed orally, taken up by hepatocytes primarily via the organic anion transporting polypeptide OATP1B1 and OATP1B3, and only minimally metabolized by CYP2C9, which accounts for roughly 10% of its clearance. Biliary and renal excretion of unchanged drug dominate the elimination picture [1].

This narrow CYP footprint is why rosuvastatin carries far fewer herb-drug interactions than simvastatin or atorvastatin, both of which rely heavily on CYP3A4. Any supplement that inhibits or induces CYP3A4 barely moves rosuvastatin plasma concentrations [2].

OATP1B1 Is the Gate That Actually Matters

OATP1B1 (gene: SLCO1B1) is the hepatic transporter responsible for pulling rosuvastatin out of portal blood and into liver cells where it inhibits HMG-CoA reductase. Drugs that inhibit OATP1B1, such as cyclosporine or gemfibrozil, can raise rosuvastatin AUC by 2- to 7-fold and dramatically increase myopathy risk [1].

Ashwagandha (Withania somnifera) has not been shown to inhibit OATP1B1 in published in vitro or clinical pharmacokinetic studies as of 2025. That absence of OATP1B1 inhibition is the single most important fact in this interaction assessment.

BCRP Efflux and Rosuvastatin Bioavailability

Breast cancer resistance protein (BCRP) limits rosuvastatin intestinal absorption. Inhibiting BCRP raises rosuvastatin exposure. Rosuvastatin prescribing information specifically flags BCRP inhibitors as interaction risks [3]. Withanolides, the principal bioactive compounds in ashwagandha, have not demonstrated clinically relevant BCRP inhibition in published literature [4].

Does Ashwagandha Directly Affect Rosuvastatin Blood Levels?

Direct pharmacokinetic data on the ashwagandha-rosuvastatin combination are limited. No dedicated human drug-drug interaction trial has been published as of January 2025. The available mechanistic evidence, however, points toward a low interaction probability for the following reasons.

CYP2C9 Activity

A 2003 in vitro study screened Withania somnifera root extract against a panel of CYP enzymes. The extract showed weak inhibitory constants (Ki) against CYP3A4 and CYP2D6 at concentrations likely exceeding typical supplemental doses, and minimal signal against CYP2C9 [5]. Because rosuvastatin depends on CYP2C9 for only a fraction of its metabolism, even partial CYP2C9 inhibition would produce a modest AUC increase well within the rosuvastatin safety margin.

P-glycoprotein and Efflux Transporters

Rosuvastatin is a substrate of P-glycoprotein (P-gp) at the intestinal level, though P-gp plays a secondary role relative to BCRP. Ashwagandha constituents, particularly withaferin A, showed P-gp inhibitory properties in one 2011 cell-line study, but at concentrations approximately 10- to 50-fold higher than those observed after oral supplementation in humans [4]. The clinical relevance is likely negligible.

Pharmacodynamic Interactions: The Thyroid Connection

This is where the clinically meaningful conversation starts. Rosuvastatin's lipid-lowering efficacy is partly dependent on thyroid hormone status. Hypothyroidism raises LDL-C through reduced hepatic LDL receptor expression and decreased LDL clearance [6]. Patients with undiagnosed or undertreated hypothyroidism may respond poorly to statin therapy.

Ashwagandha has reproducible thyroid-stimulating activity in controlled trials.

Evidence from Human RCTs

A randomized, double-blind, placebo-controlled trial published in the Journal of Alternative and Complementary Medicine (N=50 adults with subclinical hypothyroidism) tested ashwagandha root extract 600 mg daily for 8 weeks. Serum TSH decreased significantly, while T3 and T4 levels rose, compared with placebo (P<0.05 for all three markers) [7]. An earlier smaller RCT (N=20) replicated elevated T3 and T4 after 20 days of ashwagandha supplementation [8].

These findings suggest ashwagandha could improve thyroid function in subclinically hypothyroid statin users, which would augment LDL receptor upregulation and enhance rosuvastatin's effectiveness rather than oppose it. The interaction, where it exists, may actually be additive in the favorable direction for lipid outcomes.

What This Means Clinically

For a rosuvastatin patient with normal thyroid function, the thyroid effect of ashwagandha is unlikely to produce a clinically significant shift. For a patient with existing thyroid disease or who is taking levothyroxine, the thyroid-stimulating effect of ashwagandha introduces more complexity, and endocrinology involvement is warranted before combining the two.

The Cortisol-Lipid Axis: A Subtler Pharmacodynamic Pathway

Chronic cortisol elevation drives dyslipidemia. Cortisol stimulates hepatic VLDL synthesis, suppresses lipoprotein lipase activity, and raises triglycerides and LDL-C through well-characterized mechanisms [9]. This means an adaptogen that significantly lowers cortisol could independently improve the lipid profile in stressed patients.

Cortisol Reduction Data

A 2012 double-blind, randomized, placebo-controlled trial published in the Indian Journal of Psychological Medicine (N=64) demonstrated that 300 mg of KSM-66 ashwagandha root extract twice daily for 60 days reduced serum cortisol by 27.9% compared with a 7.9% reduction in the placebo group (P<0.0001) [10]. Participants also showed reductions in perceived stress scores and improved self-reported wellbeing.

A modest cortisol-driven improvement in lipids could theoretically complement rosuvastatin's direct HMG-CoA reductase inhibition. The combined effect on LDL-C has not been studied in a single trial, so the magnitude of any combination cannot be quantified from existing data.

Myopathy Risk: Does Ashwagandha Raise the Statin Side-Effect Profile?

Statin-associated muscle symptoms (SAMS) affect an estimated 7 to 29% of statin users in observational data, though randomized blinded trials report lower rates [11]. The mechanism involves mitochondrial dysfunction, CoQ10 depletion, and impaired isoprenoid signaling in skeletal muscle cells.

Ashwagandha and Skeletal Muscle

The interaction concern runs in an unexpected direction here. Ashwagandha has demonstrated muscle-protective and muscle-building properties in controlled trials, not muscle-damaging ones. A randomized, double-blind, placebo-controlled study published in the Journal of the International Society of Sports Nutrition (N=57 healthy adults) found that 300 mg of ashwagandha root extract twice daily for 8 weeks significantly increased muscle strength and recovery compared with placebo (P<0.05) [12].

No published case reports or pharmacovigilance signals describe ashwagandha worsening statin myopathy as of 2025. The FDA Adverse Event Reporting System (FAERS) does not list a specific rosuvastatin-ashwagandha muscle signal [3].

Practical Myopathy Monitoring

Even without a documented interaction, any patient starting a new supplement while on a statin should know the warning signs: unexplained muscle pain, weakness, or dark urine. These symptoms warrant immediate creatine kinase (CK) testing and temporary cessation of both the supplement and the statin pending evaluation.

Ashwagandha and Testosterone: Indirect Relevance to Statin Users

Ashwagandha raises testosterone in men with low-normal levels. A 2019 prospective, double-blind, randomized, placebo-controlled study in men with infertility (N=43) found that 675 mg of ashwagandha root extract daily for 90 days increased serum testosterone by 17% compared with baseline, while the placebo group showed no significant change [13]. A separate 2015 study (N=57 men under resistance training) reported a 15% testosterone increase over 8 weeks [12].

This is relevant because testosterone modulates HDL-C and LDL-C. Physiologically low testosterone correlates with higher LDL-C and lower HDL-C in observational data [14]. A testosterone-raising supplement in a hypogonadal statin user could therefore contribute to an incrementally improved lipid panel over time, though this effect is indirect and modest.

Specific Populations Where Caution Is Warranted

Not every rosuvastatin patient carries the same risk profile for ashwagandha interaction.

Thyroid Disease

Patients on levothyroxine or with Graves' disease should discuss ashwagandha with their prescribing physician before starting. The thyroid-stimulating effects documented at 600 mg per day could shift TSH out of target range and alter levothyroxine dosing requirements [7].

Autoimmune Conditions

Rosuvastatin is prescribed in patients with autoimmune disease (lupus, rheumatoid arthritis) partly for its pleiotropic anti-inflammatory effects. Ashwagandha has immunomodulatory properties. A 2021 review published in Phytomedicine noted that withanolides activate natural killer cells and modulate T-helper cell balance [15]. In patients on immunosuppressants, this immune activation is a reason for caution, though the interaction with rosuvastatin itself is not mechanistic.

Pregnancy and Lactation

Ashwagandha is traditionally used as an abortifacient in Ayurvedic medicine. No safe dose has been established in pregnancy [16]. Rosuvastatin is FDA category X in pregnancy. Neither should be used during pregnancy, making the combination question moot in that context [3].

Recommended Monitoring Protocol

A structured monitoring approach reduces uncertainty when combining ashwagandha with rosuvastatin.

Baseline Labs Before Starting Ashwagandha

Obtain the following before starting ashwagandha in a rosuvastatin patient:

• Fasting lipid panel (LDL-C, HDL-C, triglycerides, total cholesterol)
• TSH, free T3, free T4
• CK (creatine kinase) to establish a personal baseline
• Liver function tests (ALT, AST) if not recently checked

Follow-Up at 8 to 12 Weeks

Recheck fasting lipid panel and TSH at 8 to 12 weeks. A rosuvastatin patient starting a thyroid-active supplement who sees unexpected TSH drift should pause ashwagandha and recheck TSH in 4 weeks. Improved LDL-C numbers beyond what rosuvastatin alone would predict may warrant a dose-review conversation with the prescriber.

Dosing Considerations

No dose-separation window is required for the ashwagandha-rosuvastatin combination, because the interaction is not driven by competitive absorption in the GI tract. Rosuvastatin can be taken at any time of day; ashwagandha is typically taken with food to minimize GI upset.

Most clinical trials used 300 to 600 mg of standardized root extract (KSM-66 or Sensoril) once or twice daily. Doses above 1,000 mg per day have not been well characterized in long-term human safety studies [16].

The American Heart Association 2019 guidelines on dietary supplements state: "Evidence is insufficient to recommend routine use of dietary supplements for cardiovascular risk reduction in patients already receiving guideline-directed medical therapy." Rosuvastatin is a guideline-directed therapy; ashwagandha is an adjunct, not a replacement [17].

What Prescribers and Patients Should Tell Each Other

Disclosure gaps are a real clinical problem. A 2019 survey cited by the National Institutes of Health found that approximately 69% of patients do not inform their physicians about dietary supplement use [18]. For statin patients, that number matters because some supplements, including red yeast rice (which contains natural monacolin K, a statin-equivalent compound), create genuine double-dosing risks.

Ashwagandha does not create a double-dosing risk with rosuvastatin. Still, disclosure allows the prescriber to interpret future TSH or lipid changes accurately, order appropriate monitoring, and counsel on stopping criteria if unexpected symptoms appear.

Patients should report any of the following after starting ashwagandha while on rosuvastatin:

• New muscle pain, weakness, or tenderness (possible SAMS, evaluate CK)
• Palpitations, heat intolerance, or unexpected weight loss (possible thyroid over-stimulation)
• Unusual fatigue or weight gain (paradoxical hypothyroid worsening in rare cases)
• Elevated liver enzymes on routine labs (ashwagandha hepatotoxicity has been documented in rare case reports) [19]

Summary of the Interaction Classification

The ashwagandha-rosuvastatin interaction is best classified as an indirect pharmacodynamic interaction of low to moderate clinical significance, depending on thyroid status. It is not a pharmacokinetic interaction driven by shared enzyme or transporter competition. The ACC/AHA 2022 cholesterol guidelines note that statin efficacy monitoring should account for secondary causes of dyslipidemia including thyroid dysfunction [20]. Because ashwagandha modulates thyroid hormones, it qualifies as a factor that could shift secondary cause status and alter how a prescriber interprets a patient's lipid response.

A baseline TSH before starting ashwagandha, and a follow-up lipid panel and TSH at 8 to 12 weeks after initiation, are the two concrete actions that reduce clinical uncertainty in this combination.